“Vaccines are an essential intervention to stop the epidemic”. It’s essential that everyone eligible be vaccinated as soon as possible. A review of the existing data shows that protection against symptomatic COVID-19 in some groups starts to decrease with time.
In India, a large proportion of the eligible population has already received at least one shot since the Covid immunization campaign began in January.
FDA asked for follow-up studies to see how often those who had received a second dose of the main vaccination series had it. According to the FDA, individuals who were immunized early had somewhat lower rates of COVID-19 breakthrough, compared to those who received the vaccine later.
In India, Union Health Minister Mansukh Mandaviya announced the resumption of the ‘Vaccine Maitri’ campaign, a humanitarian effort to distribute Covid-19 vaccinations to countries worldwide.
Why do we need booster doses and who should get them first?
When US Vice President Joe Biden received his third dosage of Pfizer BioNTech’s mRNA immunization on Monday, the debate about booster doses of Covid-19 vaccines heated up. Boosters have long been debated throughout the world.
A COVID booster shot is a dosage of a vaccine administered after the protection conferred by the first injection has started to decrease. After the initial dose wears off, a COVID booster injection is required to maintain the degree of protection. A booster is usually given after the initial dose(s) wear off the immunological response.
The FDA says a booster dose of Pfizer-BioNTech COVID-19 vaccine may help prevent COVID-19. Both the FDA-approved COVID-19 vaccine and the Comirnaty vaccine are made by Pfizer-BioNTech and may be used interchangeably. It’s important to note that the FDA-authorized Pfizer-BioNTech COVID-19 Vaccine is the same formulation as the FDA-approved Comirnaty and the vaccines may be used interchangeably.
Booster dosages are suggested for specific segments of the population, and the decision to provide a third dose is based on the patient’s future risk of developing severe Covid-19. Cancer patients, the elderly, and individuals who have had substantial occupational exposure to infection (such as health professionals) should get booster doses because they are clinically susceptible or considerably exposed to the risk of infection.
The FDA modified the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to enable a single booster dose six months following the main series in people above the age of sixty-five, risk factors for severe COVID-19 in people aged 18 to 64; and Individuals aged 18 to 64 who are often exposed to SARS-CoV-2 in the workplace or institutions.
The booster doses are administered in the same manner as the original immunizations. Pfizer-BioNTech submitted the first vaccine authorization request to the FDA in November 2020; Moderna followed about ten days later, and Johnson&Johnson-Janssen in February 2021. The FDA authorized them all for emergency use based on two-month follow-up data confirming the injections’ safety and efficacy, with Pfizer-BioNTech receiving approval first, followed by Moderna and Johnson&Johnson-Janssen.
Immunization plan to address future Health Care Needs
According to the US Vice President Joe Biden, the Quad cooperation between the United States, India, Japan, and Australia is “on track to help produce at least 1 billion vaccine doses in India to boost global supply by the end of 2022”.
Joe Biden also stated that the US would buy 1 billion doses of Pfizer’s Covid-19 vaccine to distribute with the globe, aiming to vaccinate 70% of the worldwide population within a year.
The US also pledged $380 million to the Global Vaccine Alliance — GAVI — to help provide vaccines in the most needy areas.
A health minister in India has stated that the “Vaccine Maitri” programme would begin in October with the production of over 30 crore doses and a total of over 100 crore vaccines in the next quarter. This vaccine will be made accessible to countries all over the globe.